TORONTO, ONTARIO--(Marketwire - Aug. 14, 2012) - Gemoscan Canada, Inc. (TSX VENTURE:GES) (MUN:1GE)
With statistics demonstrating that nearly 30 percent of Canadians may be affected by food sensitivities, access to affordable and comprehensive food intolerance based nutrition and diet management systems are more important than ever before. Starting today, Rexall™ and Rexall™ Pharma Plus™ stores across Canada will be even better equipped to meet this demand with the introduction of HEMOCODE™ Lite. Based on the popular HEMOCODE™ Food Intolerance System, which clarifies and helps people deal with sensitivities to 250 foods and additives, HEMOCODE™ Lite now targets and manages for sensitivities to 60 of the most common foods.
"This is one more way Rexall is making it easier for Canadians to feel good about their health," said Tracey Phillips, Vice President, Pharmacy, Rexall. "We're pleased to exclusively provide a lower-priced option for food intolerance testing with HEMOCODE™ Lite and add to our many services and products that help Canadians identify, relieve and prevent digestive issues."
HEMOCODE™ Lite provides easier access to those Canadians who are looking for improved wellness through diet, but may also be looking for a more gradual and lower-priced option.
"Food intolerances can impede a variety of processes that occur in a healthy body. Managing your intolerances can restore healthy function and may make your body more efficient at absorbing the vitamins and minerals you need. Most people also note, not only improvements in their welfare, but a feeling of greater energy and overall wellness, after engaging with Hemocode" stated Dr. Mubina Jiwa, ND.
Those suffering from food intolerances may experience pain and discomfort that often adversely affects their daily functioning. Without proper management of the offending foods, consumers may suffer unnecessarily for years or even a lifetime. As with the original, HEMOCODE™ Food Intolerance System, with just a few drops of blood, HEMOCODE™ Lite delivers a program, developed and administered by licensed doctors of naturopathic medicine, that includes: a comprehensive report of offending foods complete with personalized information and recommendations for dietary wellness; regular naturopathic consultation; easy-to-follow instructions and handy tools to help you in feeling your best, but, at a lower-price.
"As food intolerances have become better understood in the scope of diet and nutritional wellness, the need for all Canadians to have greater access to a management tool like HEMOCODE™ has never been more important," says Dr. Mubina Jiwa, Doctor of Naturopathic Medicine.
HEMOCODE™ Lite is available exclusively at Rexall™ and Rexall™ Pharma Plus™ stores nationwide for $129 and may be covered through extended health care programs under naturopathy.
ABOUT THE HEMOCODE™ FOOD INTOLERANCE SYSTEM
The HEMOCODE™ Food Intolerance System is a personalized naturopathic nutritional program that promotes dietary well-being. It uses patented technology and services to provide consultation and recommendations to simplify the management of food sensitivities. The HEMOCODE™ Food Intolerance System is one of a growing number of wellness services and products offered by pharmacies as complementary medical choices. Complementary medicine is an adjunct to conventional medical practice, incorporating alternative modalities and therapies with a focus on lifestyle and wellness. A statistically significant base of practitioners and those using HEMOCODE™ report improved dietary wellness and satisfaction.
ABOUT GEMOSCAN CANADA, INC.
Gemoscan is an industry leader in food intolerance management and maintains a first-to-market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology; Gemoscan develops, owns and markets comprehensive food sensitivity and dietary management solutions for consumers, including the HEMOCODE™ Food Intolerance System, a personalized naturopathic nutritional program that promotes well-being. Gemoscan is the first and only provider to commercialize a food intolerance management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available.
Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange (TSX-V) under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.
Rexall is a national drugstore chain of 420 Rexall and Rexall Pharma Plus retail pharmacies located across Canada with a heritage dating back to 1904. Rexall is focused on helping to make it easier for Canadians to live healthier lives through community-focused pharmacy services, quality health care products and working to continually enhance the customer experience. For more information visit www.rexall.ca.
This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.